These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31162548)

  • 1. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
    Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
    J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway.
    Wang C; Tan C; Wen Y; Zhang D; Li G; Chang L; Su J; Wang X
    Cell Death Dis; 2019 Jun; 10(7):499. PubMed ID: 31235696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/β-catenin pathway.
    Cong J; Gong J; Yang C; Xia Z; Zhang H
    BMC Cancer; 2021 Jan; 21(1):2. PubMed ID: 33397320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
    Cao L; Gao H; Li P; Gui S; Zhang Y
    Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
    Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
    J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.
    Tan Z; Zheng H; Liu X; Zhang W; Zhu J; Wu G; Cao L; Song J; Wu S; Song L; Li J
    Oncotarget; 2016 Apr; 7(17):24076-87. PubMed ID: 26992223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
    Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
    Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2.
    Chen HY; Lang YD; Lin HN; Liu YR; Liao CC; Nana AW; Yen Y; Chen RH
    Sci Rep; 2019 Jul; 9(1):9687. PubMed ID: 31273221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-139-5p regulates C2C12 cell myogenesis through blocking Wnt/β-catenin signaling pathway.
    Mi L; Li Y; Zhang Q; Zhao C; Peng Y; Yang G; Zheng X
    Biochem Cell Biol; 2015 Feb; 93(1):8-15. PubMed ID: 25529604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
    Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
    Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
    BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
    Kong LY; Xue M; Zhang QC; Su CF
    Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
    Yue X; Cao D; Lan F; Pan Q; Xia T; Yu H
    Neuro Oncol; 2016 Sep; 18(9):1288-96. PubMed ID: 27006177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
    Bai J; Gui S; Zhang Y
    J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
    Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
    Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-34a Inhibits Breast Cancer Proliferation and Progression by Targeting Wnt1 in Wnt/β-Catenin Signaling Pathway.
    Si W; Li Y; Shao H; Hu R; Wang W; Zhang K; Yang Q
    Am J Med Sci; 2016 Aug; 352(2):191-9. PubMed ID: 27524218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
    Zhao W; Yang S; Chen J; Zhao J; Dong J
    Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TTPAL Promotes Colorectal Tumorigenesis by Stabilizing TRIP6 to Activate Wnt/β-Catenin Signaling.
    Gou H; Liang JQ; Zhang L; Chen H; Zhang Y; Li R; Wang X; Ji J; Tong JH; To KF; Sung JJY; Chan FKL; Fang JY; Yu J
    Cancer Res; 2019 Jul; 79(13):3332-3346. PubMed ID: 31018940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-452 promotes an aggressive colorectal cancer phenotype by regulating a Wnt/β-catenin positive feedback loop.
    Li T; Jian X; He H; Lai Q; Li X; Deng D; Liu T; Zhu J; Jiao H; Ye Y; Wang S; Yang M; Zheng L; Zhou W; Ding Y
    J Exp Clin Cancer Res; 2018 Sep; 37(1):238. PubMed ID: 30253791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.